A proposed $18.9 million class action settlement has been approved by a U.S. District Court for investors who purchased Biogen Inc. common stock between June 8 and July 12, 2021. The settlement aims to resolve claims against Biogen and certain executives, with a court hearing scheduled for September 29, 2026, to finalize approval. Investors must submit a Proof of Claim by September 24, 2026, to participate in the settlement distribution. Those who do not opt out will be bound by the settlement terms regardless of claim submission.
A $18.9 million class action settlement has been approved for investors who bought Biogen Inc. common stock between June 8 and July 12, 2021. The settlement resolves claims against Biogen and certain executives, with a court hearing scheduled for Sep...
Biogen announced it will showcase new data on its Alzheimer’s disease treatments at the AAIC 2026 conference in London, including Phase 2 results from the CELIA study of diranersen, a tau-targeting antisense oligonucleotide. The data includes clinica...
Pomerantz LLP is investigating Biogen and some of its executives for potential securities fraud following the company's announcement that its Alzheimer's drug trial failed to meet the primary endpoint. On May 14, 2026, Biogen reported Phase 2 trial r...
